Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Love the spin lol... that is a boiler plate statement that all public companies are required to use with respect to forward looking statements.
Look it up... nothing unusual with this
Couldn't agree more...those that bought in yesterday were looking for a pop... so they could sell.... pps will rebound to .11
He said he does not know why the stock has been flat despite all the positive developments.... big difference
Remember when people were saying that the FDA were going to require PMCB to start over with phase 1 trials haha... just jumped to a pivotal trial
No it's just about statistical significance and standard deviation of the data
The redesign is so that we can jump to a pivotal trial.... this is skipping a step and basically just means a larger # if patients are required
He basically laid out the trial design for us on the call... they have everything they need except their decision as to what drug to run in the control arm...
Any other redesign was related to imaging endpoint frequency of imaging and patients # needed.... this is simple stuff... and the FDA gave them all the info they needed
I thinks that the plan was to have the IND package submitted by the time of the conference call and they wanted to give us Pre-IND meeting update and also be able to say that they have filed for IND as well.
Sounds to me that everything is in order for the IND package submission with the exception of determining what drug will be in place in the control arm. (Glad they are taking due time with this)
Imho... I think there is very little left to figure out before they can submit IND.... I think less than a month
There will also be a release summarizing the call before open on wed
It will be recorded
See my previous post about a hostile takeover vs a structured buyout...
TD2 and facet serve very different functions...both of which are needed
There is never more sales than buys.... they are always equal. Has to be a buyer for every sale.
What you are referring to is transactions taking place at the bud price vs. the ask
The price goes up because the bid and ask are always changing plus the end of day price is just the the last transaction.... that's why mms put up a wall at the ask if they want to keep the price down
There is a lot of wash trading going on. Driving the price down so they can buy.... then letting it run to sell. Repeating this over and over allows them to increase their holdings without additional capital (shaking weak hands)
Imho they know this will explode on the 8th. I wish the date wasn't released so they wouldn't know the timing. This would add risk to this wash trading. However right now their goal is to acquire as many shares as they can before the news is out (by keeping the pps below .12 ( buying high selling low)
I sold all of mine @.41 and bought back in from .12 to .04 that how I got so many shares.
But that was different... that run was on mjna hype... no real news and too far away from trials. I would hat to sell my shares and have it jump before I can buy back in... the next run may be permanent
Assuming he announces the green light for IND - .16-.20
If he announce breakthrough designation or fast track approval...18-.25
Alternate funding opposed to the chardan ATM agreement would also boost the pps
The magic happens at buyout or trial results
And happy to help PETE host
Pete... I'm catching you in share count. ;)
Agreed today was totally unrealistic... just don't want to set expectations for tomorrow either.
I'd be surprised if we get an update tomorrow... Thursday makes more sense. I have worked for many small public companies and coordinating with PR companies and press releases alway get delayed by more important work
Frost, I disagree but do respect you opinion. First I am obviously betting this doesn't happen. Second if it did it would not be anywhere near as costly or time consuming as you think
Even if FDA pushes this to phase 1... which I think is extremely unlikely... given... this is a delivery device delivering already approved drugs at 1/3 the dose currently used... risk to patient is none.
But even if it happened no way it drops to year lows... we won't cross .10 again
Good luck... I'm most likely a buyer all the way through trial results ... .20 or .30 is still now where near where I think it will be at the hard stop
Honestly, IND approval is a big deal. I think this could be your last chance to get in below .15 ... news of the FDA granting IND status could happen tomorrow, next week... once this happens trial can commence... I'm buying all that I can as soon as I can
Nope... it's just a meeting. We may not have an answer on IND for 30 days. IND is not the same as the FDA approving CIAB (not a drug either). We have a long way to go here... tomorrow is a big step ... but there are many more
There are many scenarios for a buyout... that's why you can't get a straight answer.
There are two main type of buyouts a cash buy out and a share exchange. (Many others as well)
Cash your is simple at $x per share the stock pmcb ceases to exist and you get paid.
Share exchange the buying company issue x # of share of their company for each share of pmcb.
To further complicate this ... I doubt that pmcb sells their company but rather the rights to the use of Ciab or Licsenses it for the pancreatic cancer treatment ... and used the proceeds to fund the diabetes trial and other trials. Under this scenario it will likely be a cash payment lump some or payments over time. Either way the share price will skyrocket. It would be up to you whether you sell or hold for the big diabetes payout
Great post. I have seen this happening already as the shift has begun
Thank you... I knew I was close. Appreciate you diging for the quote
I believe that I remember him saying two years ... maybe a lot longer
Yes I agree that's possible.... and may even be likely... just not what I am expecting. If they do request changes... it will take a little more time... but that's ok with me. Let's do this right and knock the cover off the ball
I am a believer in this company...
however I do believe that it is very unlikely that they give the ok without any changes to trial design ( option 1)
Option 2 - is the most likely in my opinion... a few tweaks and recommendations to the trial design
Option 3 - back to phase 1 ... is a possibility but I believe it is very unlikely.... as unlikely as option 1.... many drugs have been approved with very old phase 1 data... and remember we are not testing a drug but rather the bioinert membrane ( the delivery method for an already approved drug) this alleviates much of the patient safety concerns that are often the cause of the FDA reverting back to phase 1 when the data is old
Maybe it's just me but... I couldn't care less what happens to the ops in the next 6 months.
All that matters to me now getting through trials. Hopefully we have some SLOW steady growth such that shares trade hands and average entry price increases creating more support . A large spike from media will just entice day traders and increase volatility.
I'm focused on the end game... what happens between now and then doesn't really matter as I'm not selling and more than happy to add at prices far higher than the 12 month high (.16+)
Agreed... I picked up 1m last December when this plummeted... I love these days!
Congrats PETE... I got 200000 too... but at .109. I am very happy!
I know most of you like to see the PPS go up up and up...but that's not realistic after the release of the ind meeting date. Now we know nothing material will be released until the back half of the month...before the release of the date no one knew when news was likely. Much less risk until after the 17th. Last chance to walk it down before the next jump.!
Personally I hope it drop low... if so my next 20k buy will just get me more share that I am confident will bounce
My guess is that the FDA meeting has already happened... there would be no advantage to publishing the meeting date... I believe we won't hear about how the meeting went until 30 days after the meeting (the automatic approval date). At this time Pmcb will tell us is they have the green light or if the need to answer more questions for the FDA
Imho I think this bounces end of day to .1425 range then to mid .15 first day of new year. We will likely be in the .15-.17 range until news on trial start date
Not to answer for you here PETE, but my take is this decline today has nothing to do with the chardan deal. This is just a pullback from profit taking after the 400% run over the last month. MMs may be manipulating so they can shake weak hands and get in before the next run.
The smart investors who sold today, bought back in .... Just a way to increase shares for the long run. This will bounce strong in the new year. Personally I won't sell even if it declines another 20% ... Don't want to miss the bounce by being greedy.
I am long and am looking at the potential value a year from now... Even if they use chardan and dilute the stock ... The value increase after the trial will be 10 fold the impact of the dilution . My opinion only